» Articles » PMID: 7471600

Effects on Exercise Tachycardia During Forty-eight Hours of a Series of Doses of Atenolol, Sotalol, and Metoprolol

Overview
Publisher Wiley
Specialty Pharmacology
Date 1981 Mar 1
PMID 7471600
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Beta adrenoceptor blockers differ mainly in their plasma elimination half-lives (t 1/2 s). It has been assumed that drugs with longer t 1/2 will have a longer duration of effect on exercise tachycardia. Several factors may influence the duration of action of beta blockers; we have investigated the contribution of plasma elimination t 1/2 and dose by comparing the effects on an exercise tachycardia in healthy subjects of placebo, 25, 50, 100, and 200 mg of atenolol and of sotalol, and 50, 100, 200, and 400 mg metoprolol. Subjects exercised before and at 2, 3, 6, 8, 24, 33, and 48 hr after oral doses of each drug. Plasma samples for measurement of drug concentration were drawn before each exercise period. Twenty-four hours after 50, 100, and 200 mg atenolol and 50, 100, 200, and 400 mg sotalol there were reductions in an exercise tachycardia; at this time reductions were greater after the larger doses. The plasma elimination t 1/2s of atenolol were between 7.2 +/0 1.0 hr. Although 50, 100, and 200 mg metoprolol induced the same reductions in an exercise tachycardia 2 hr after drug as 25, 50, and 100 mg atenolol and 50, 100, and 200 mg sotalol, these doses were without effect at 24 hr. Metoprolol 400 mg reduced exercise tachycardia at 24 hr but the effect was less than that of the three largest doses of atenolol and sotalol. The plasma elimination t 1/2 for metoprolol was between 3.6 +/- 0.6 and 5.0 +/- 1.8 hr. These results show that duration of cardiac beta blocking of cardiac beta blocking activity of atenolol, sotalol, and metoprolol is determined by the elimination t 1/2 and dose.

Citing Articles

Chronotropic incompetence, echocardiographic abnormalities and exercise intolerance in renal transplant recipients.

Ma M, Zuo M, Yap D, Mok M, Kwan L, Chan G J Nephrol. 2014; 27(4):451-6.

PMID: 24756970 DOI: 10.1007/s40620-014-0091-y.


Therapeutic drug monitoring of antiarrhythmic drugs.

Jurgens G, Graudal N, Kampmann J Clin Pharmacokinet. 2003; 42(7):647-63.

PMID: 12844326 DOI: 10.2165/00003088-200342070-00004.


A placebo controlled comparison of the effects of metoprolol and celiprolol on echo-Doppler measurements of cardiovascular function in normal volunteers.

Silke B, Thompson A, Leitch A, Riddell J Br J Clin Pharmacol. 1995; 40(1):37-42.

PMID: 8527266 PMC: 1365025. DOI: 10.1111/j.1365-2125.1995.tb04532.x.


Ambulatory blood pressure during once-daily randomised double-blind administration of atenolol, metoprolol, pindolol, and slow-release propranolol.

Floras J, Jones J, Hassan M, Sleight P Br Med J (Clin Res Ed). 1982; 285(6352):1387-92.

PMID: 6814568 PMC: 1500409. DOI: 10.1136/bmj.285.6352.1387.


Antihypertensive activity of once daily metoprolol alone and with chlorthalidone and comparison with a twice daily regimen.

MUIESAN G, Agabiti-Rosei E, Carotti A, Corea L, Innocenti P, Montervino C Eur J Clin Pharmacol. 1982; 23(3):209-13.

PMID: 6756932 DOI: 10.1007/BF00547555.